Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Tasquinimod targets suppressive myeloid cells in the tumor microenvironment.

Literature DB >> 31646064

Tasquinimod targets suppressive myeloid cells in the tumor microenvironment.

Abstract

Infiltrating myeloid derived suppressor cells and tumor-associated macrophages (TAMs) are important components of the immunosuppressive tumor microenvironment. We recently reported that tasquinimod, which binds to S100A9, impairs both infiltration and function of these cells. Here we discuss the underlying mechanisms responsible for targeting multiple suppressive populations and the modulation of the tumor microenvironment.

Entities: Chemical Disease Gene

Keywords: S100A9; Tasquinimod; immunotherapy; myeloid-derived suppressor cells (MDSCs); suppressive myeloid cells (SMCs); tumor associated macrophages (TAMs)

Year: 2018 PMID： 31646064 PMCID： PMC6791429 DOI： 10.1080/2162402X.2015.1072672

Source DB: PubMed Journal: Oncoimmunology ISSN： 2162-4011 Impact factor: 8.110

10 in total

1. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.

Authors: Roberto Pili; Michael Häggman; Walter M Stadler; Jeffrey R Gingrich; Vasileios J Assikis; Anders Björk; Orjan Nordle; Goran Forsberg; Michael A Carducci; Andrew J Armstrong
Journal: J Clin Oncol Date: 2011-09-19 Impact factor: 44.544

2. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells.

Authors: Pratima Sinha; Chinonyerem Okoro; Dirk Foell; Hudson H Freeze; Suzanne Ostrand-Rosenberg; Geetha Srikrishna
Journal: J Immunol Date: 2008-10-01 Impact factor: 5.422

Review 3. Antigen specificity of immune suppression by myeloid-derived suppressor cells.

Authors: Samantha Solito; Vincenzo Bronte; Susanna Mandruzzato
Journal: J Leukoc Biol Date: 2011-04-12 Impact factor: 4.962

4. Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models.

Authors: Li Shen; Anette Sundstedt; Michael Ciesielski; Kiersten Marie Miles; Mona Celander; Remi Adelaiye; Ashley Orillion; Eric Ciamporcero; Swathi Ramakrishnan; Leigh Ellis; Robert Fenstermaker; Scott I Abrams; Helena Eriksson; Tomas Leanderson; Anders Olsson; Roberto Pili
Journal: Cancer Immunol Res Date: 2014-11-04 Impact factor: 11.151

Review 5. Altered macrophage differentiation and immune dysfunction in tumor development.

Authors: Antonio Sica; Vincenzo Bronte
Journal: J Clin Invest Date: 2007-05 Impact factor: 14.808

6. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment.

Authors: Cesar A Corzo; Thomas Condamine; Lily Lu; Matthew J Cotter; Je-In Youn; Pingyan Cheng; Hyun-Il Cho; Esteban Celis; David G Quiceno; Tapan Padhya; Thomas V McCaffrey; Judith C McCaffrey; Dmitry I Gabrilovich
Journal: J Exp Med Date: 2010-09-27 Impact factor: 14.307

Review 7. Myeloid-derived suppressor cells as regulators of the immune system.

Authors: Dmitry I Gabrilovich; Srinivas Nagaraj
Journal: Nat Rev Immunol Date: 2009-03 Impact factor: 53.106

8. S100A9 interaction with TLR4 promotes tumor growth.

Authors: Eva Källberg; Thomas Vogl; David Liberg; Anders Olsson; Per Björk; Pernilla Wikström; Anders Bergh; Johannes Roth; Fredrik Ivars; Tomas Leanderson
Journal: PLoS One Date: 2012-03-28 Impact factor: 3.240

9. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein.

Authors: Pingyan Cheng; Cesar A Corzo; Noreen Luetteke; Bin Yu; Srinivas Nagaraj; Marylin M Bui; Myrna Ortiz; Wolfgang Nacken; Clemens Sorg; Thomas Vogl; Johannes Roth; Dmitry I Gabrilovich
Journal: J Exp Med Date: 2008-09-22 Impact factor: 14.307

10. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides.

Authors: Per Björk; Anders Björk; Thomas Vogl; Martin Stenström; David Liberg; Anders Olsson; Johannes Roth; Fredrik Ivars; Tomas Leanderson
Journal: PLoS Biol Date: 2009-04-28 Impact factor: 8.029

10 in total

6 in total

Tasquinimod targets suppressive myeloid cells in the tumor microenvironment.

1. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.

2. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells.

Review 3. Antigen specificity of immune suppression by myeloid-derived suppressor cells.

4. Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models.

Review 5. Altered macrophage differentiation and immune dysfunction in tumor development.

6. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment.

Review 7. Myeloid-derived suppressor cells as regulators of the immune system.

8. S100A9 interaction with TLR4 promotes tumor growth.

9. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein.

10. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides.

Review 1. Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy.

Review 2. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets.

Review 3. Friend or Foe: S100 Proteins in Cancer.

4. In-Depth Immune-Oncology Studies of the Tumor Microenvironment in a Humanized Melanoma Mouse Model.

Review 5. Host-Directed Therapies: Modulating Inflammation to Treat Tuberculosis.

Review 6. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer.